ISABELLA WASZKIEWICZ: Open Payments
NPI 1467084855 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,508 in 148 payments from 13 companies in 2025. Trend: 2023 $1,111 · 2024 $3,164 · 2025 $3,508
Food & beverage: $3,428Education: $80
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 41 | $655 |
| Neurocrine BioSciences, Inc. | 18 | $608 |
| Teva Pharmaceuticals USA, Inc. | 19 | $564 |
| Alkermes, Inc. | 16 | $419 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $370 |
| E.R. Squibb & Sons, L.L.C. | 6 | $294 |
| Axsome Therapeutics, Inc. | 8 | $230 |
| Janssen Pharmaceuticals, Inc | 5 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $91 |
| Bausch Health US, LLC | 3 | $67 |
Products named: VRAYLAR, INGREZZA, AUSTEDO XR, CAPLYTA, COBENFY, ARISTADA, Auvelity, LYBALVI.
Industry payments across AZ — which companies pay providers there.
